FDA proposes to withdraw Amgen's rare autoimmune disease drug

The FDA's Center for Drug Evaluation and Research proposed withdrawing approval of Amgen's Tavneos for rare autoimmune diseases, citing lack of proven effectiveness and untrue statements in the application. The agency also identified 76 cases of drug-induced liver injury, including 7 cases of vanishing bile duct syndrome, with 8 deaths reported. The move is a major regulatory and safety overhang for Amgen and could materially impact the drug's commercial outlook.

Analysis

This is less a one-off headline than a structural de-risking event for AMGN: the market is now facing a meaningful probability of removal from the revenue base, plus a much larger overhang on labeling, physician adoption, and post-marketing liability. For a rare-disease franchise, reputational damage can outlast the legal process; even if approval is ultimately preserved, prescribers tend to front-load caution immediately after a liver-safety scare, which can pressure new starts for multiple quarters.

The second-order winner is the competitive set in the vasculitis / rare autoimmune bucket, especially any therapy with cleaner hepatic safety and less regulatory uncertainty. The bigger nuance is that this may not only hit current sales, but also raise the hurdle rate for future immunology launches: regulators will likely demand stronger real-world durability and safety evidence, which can slow label expansion and compress peak-sales assumptions across adjacent rare-disease assets.

Catalyst timing is asymmetric. In the next days to weeks, the stock is exposed to headline risk, activist/regulatory commentary, and potential physician channel checks. Over months, the key question is whether the FDA pursues a formal withdrawal path or settles for label restrictions; a softer outcome could trigger a relief rally, but that would likely be smaller than the downside if access is curtailed or litigation begins to scale.

Consensus may be underestimating how sticky safety stigma is in orphan drugs: when the treated population is small and highly fragile, even limited liver-injury reports can cause outsized abandonment because risk tolerance is low and alternatives exist. That makes the downside not just a revenue haircut but a multiple compression event, as investors re-rate AMGN from a quality-growth biotech to a company with a litigious, politically sensitive asset.

Key Decisions for Investors

• Short AMGN on any pre-market bounce; trade horizon 2-6 weeks, with the thesis that regulatory overhang and physician channel risk keep pressure on the stock even if the process drags out.
• For more defined risk, buy AMGN put spreads 1-3 months out, targeting strikes around 10-15% below spot to capture a regulatory headline-driven de-rating while limiting premium bleed if the process stalls.
• Pair trade: short AMGN / long a cleaner rare-disease or immunology peer with less hepatic-safety baggage over the next 1-2 quarters; the goal is to isolate company-specific regulatory risk while staying net long healthcare.
• Avoid dip-buying AMGN until there is clarity on whether the FDA pursues withdrawal versus label restriction; the stock can remain structurally cheap for months if prescribers stay cautious.
• If you need to express the broader theme, consider a basket long in orphan-drug names with strong post-marketing safety records versus short AMGN, because the market may start discounting higher regulatory friction across adjacent rare-disease approvals.